Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claus Garbe

Showing results (401-410 of 501) with videos related to

Pageof 51
Sort By:
Cancer Medicine|October 18, 2013
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastasesHeike Niessner, Andrea Forschner, Bernhard Klumpp, et al.
Ebiomedicine|August 20, 2015
The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression AnalysisMitchell S Stark, Kerenaftali Klein, Benjamin Weide, et al.
The Lancet. Oncology|March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety studyJames Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2024
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature researchTeresa Amaral, Lena Nanz, Lina Maria Serna Higuita, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 3, 2024
Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patientsAnthony J Dixon, Athanassios Kyrgidis, Howard K Steinman, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2017
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patientsKilian Wistuba-Hamprecht, Alexander Martens, Florian Heubach, et al.
Cancer Immunology, Immunotherapy : CII|February 27, 2019
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysisBastian Schilling, Alexander Martens, Marnix H Geukes Foppen, et al.
The Lancet. Oncology|September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2021
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabKilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, et al.
Pageof 51

Showing results (401-410 of 501) with videos related to

Sort By:
Pageof 51
Cancer Medicine|October 18, 2013
Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastasesHeike Niessner, Andrea Forschner, Bernhard Klumpp, et al.
Ebiomedicine|August 20, 2015
The Prognostic and Predictive Value of Melanoma-related MicroRNAs Using Tissue and Serum: A MicroRNA Expression AnalysisMitchell S Stark, Kerenaftali Klein, Benjamin Weide, et al.
The Lancet. Oncology|March 4, 2014
Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety studyJames Larkin, Michele Del Vecchio, Paolo A Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)|December 14, 2024
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature researchTeresa Amaral, Lena Nanz, Lina Maria Serna Higuita, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 3, 2024
Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patientsAnthony J Dixon, Athanassios Kyrgidis, Howard K Steinman, et al.
European Journal of Cancer (Oxford, England : 1990)|February 8, 2017
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patientsKilian Wistuba-Hamprecht, Alexander Martens, Florian Heubach, et al.
Cancer Immunology, Immunotherapy : CII|February 27, 2019
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysisBastian Schilling, Alexander Martens, Marnix H Geukes Foppen, et al.
The Lancet. Oncology|September 17, 2018
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Paolo A Ascierto, Helen J Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)|June 6, 2021
Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)Helen Gogas, Reinhard Dummer, Paolo A Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabKilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, et al.
Pageof 51